MPN Watch

Dossier pubmed observational 09-jun-2026

Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.

Key claim: In a Thai PV cohort, 38% of patients experienced thromboembolic events (87% pre-diagnosis, 91% arterial), age ≥60 was a significant risk factor, and prior thrombosis independently predicted inferior overall survival.

Abstract

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm frequently complicated by thromboembolic events. However, data regarding thrombotic burden and long-term outcomes among Asian patients remain limited. MATERIALS AND METHODS: We conducted a retrospective cohort study at a tertiary referral center to evaluate thromboembolic events, treatment-related complications, disease progression, and overall survival in patients with PV. RESULTS: A total of 133 patients were included, with a median age of 61 years (range 18-88). Most patients were male (60.2%). Fifty-one patients (38.3%) experienced at least one thromboembolic event, with 54 events in total, of which 87% occurred before or at PV diagnosis. Arterial thrombosis accounted for 90.7% of all events. Age ≥60 years was significantly associated with thromboembolic events, with an odds ratio of 2.34 (95% confidence interval [CI], 1.07-5.11). After a median follow-up of 7.7 years, the 5-year overall survival was 82.7% (95% CI, 74.61-88.35). Prior thrombosis was associated with an increased risk of death (hazard ratio, 1.98; 95% CI, 1.15-3.42). Hydroxyurea resistance or intolerance occurred in 9.8% of patients. Bleeding complications were observed in 6.8%, including major bleeding in 4.5%. Fibrotic transformation, leukemic transformation, and secondary solid malignancies occurred in 4.5%, 3.8%, and 6.0% of patients, respectively. CONCLUSION: Thromboembolic events were common and predominantly arterial in this Asian PV cohort, occurring mainly before or at diagnosis. Prior thrombosis was associated with inferior survival. Long-term follow-up also revealed disease progression and secondary solid malignancies, underscoring the importance of continued surveillance.

Why this matters

Pending synthesis.

Source

Link

Briefing card

Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.
Stage: observational · pubmed · 09-jun-2026

In a Thai PV cohort, 38% of patients experienced thromboembolic events (87% pre-diagnosis, 91% arterial), age ≥60 was a significant risk factor, and prior thrombosis independently predicted inferior overall survival.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

🔎 Pulled in by auto-added search #25 (pubmed): "hydroxyurea"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND (resistance[Title/Abstract] OR intolerance[Title/Abstract] OR cytoreduction[Title/Abstract] OR "hematocrit"[Title/Abstract])

External: doi:10.1080/07853890.2026.2682982

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

build build 612 · 69ce4cf-dirty · 2026-11-11